Aldeyra stock crashes 68% after the FDA rejects its dry eye drug, reproxalap, for the third time. Get the full regulatory update here.
Importance Rank:
1
Aldeyra stock crashes 68% after the FDA rejects its dry eye drug, reproxalap, for the third time. Get the full regulatory update here.
Copyright © Louis Velazquez. All Rights Reserved.